Skip to main content
SpringerLink
Log in

Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

An Erratum to this article was published on 27 July 2006

Abstract

Introduction

Patients who take chronic glucocorticoids (GC) are at increased risk of osteoporosis and fracture. Only a minority of patients who take chronic GC receive optimal osteoporosis prevention, diagnosis, and/or treatment.

Methods

An organized program of care—GIOP (Glucocorticoid-Induced Osteoporosis Program)—was designed and implemented. The program goals were to identify patients at risk of fracture, provide education, redesign and implement new pathways of care, and monitor outcomes. Two hundred chronic GC users were seen at baseline, and follow-up visits scheduled at 6 months and 1 year.

Results

Patient retention of knowledge, frequent exercise, and 25-OH Vitamin D levels all significantly improved at 1 year. A significant decrease in GC dose was seen. In terms of adherence, 91% of patients considered at high risk were taking a bisphosphonate or teriparatide at 1 year, and 96% of patients overall were adherent to their prescribed regimen of calcium, vitamin D, and prescription treatment (if indicated). Bone density at the spine and total hip increased significantly.

Conclusions

GIOP is the first organized program of care for patients who take chronic GC that has demonstrated a clinically significant improvement in outcome. The program’s design can be adapted and used by other health systems and organizations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Saag KG (2003) Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin N Am 32:135–157

    Article  CAS  Google Scholar 

  2. Cohen D, Adachi JD (2004) The treatment of glucocorticoid-induced osteoporosis. J Steroid Biochem Mol Biol 88:337–349

    Article  PubMed  CAS  Google Scholar 

  3. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 44:1496–1503

    Article  Google Scholar 

  4. Brown JP, Josse RG (2002) 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167(10 Suppl):S1–S30

    PubMed  Google Scholar 

  5. Eastell R, Reid DM, Compston J et al (1998) A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 244:271–292

    Article  PubMed  CAS  Google Scholar 

  6. Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J (2002) Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis. Arthritis Rheum 46:3136–3142

    Article  PubMed  Google Scholar 

  7. Blalock SJ, Norton LL, Patel RA, Dooley MA (2005) Patient knowledge, beliefs, and behavior concerning the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 53:732–739

    Article  PubMed  Google Scholar 

  8. Naunton M, Peterson GM, Jones G, Griffin GM, Bleasel MD (2004) Multifaceted educational program increase prescribing of preventive medication for corticosteroid induced osteoporosis. J Rheumatol 31:550–556

    PubMed  Google Scholar 

  9. Solomon DH, Katz JN, La Tourette AM, Coblyn JS (2004) Multifaceted intervention to improve rheumatologists’ management of glucocorticoid-induced osteoporosis: a randomized controlled trial. Arthritis Rheum 51:383–387

    Article  PubMed  CAS  Google Scholar 

  10. Newman ED, Ayoub WT, Starkey RH, Diehl JM, Wood GC (2003) Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years. Osteoporos Int 14:146–151

    PubMed  CAS  Google Scholar 

  11. Newman ED, Ayoub WT, Matzko CK, Wood C (2003) Glucocorticoid-induced osteoporosis-significant improvement in bisphosphonate use utilizing standardized consultative DXA reporting. Arthritis Rheum 48:S499

    Google Scholar 

  12. Canalis E, Bilezikian JP, Angeli A, Giustina A (2004) Perspectives on glucocorticoid-induced osteoporosis. Bone 34:593–598

    Article  PubMed  CAS  Google Scholar 

  13. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000

    Article  PubMed  Google Scholar 

  14. Sambrook PN (2002) Glucocorticoid osteoporosis. Curr Pharm Des 8:1877–1883

    Article  PubMed  CAS  Google Scholar 

  15. Homik JJ, Cranney A, Shea BJ et al (2005) Calcium and vitamin D for corticosteroid-induced osteoporosis (Cochrane Review) (2005) In: The cochrane library, Issue 4. Wiley, Chichester, UK

  16. Lane NE (2001) An update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 27:235–253

    Article  PubMed  CAS  Google Scholar 

  17. Reid IR (2000) Glucocorticoid-induced osteoporosis. Baillieres Clin Endocrinol Metab 14:279–298

    Article  CAS  Google Scholar 

  18. Sambrook PN (2005) How to prevent steroid induced osteoporosis. Ann Rheum Dis 64:176–178

    Article  PubMed  CAS  Google Scholar 

  19. Adachi JD, Saag KG, Delmas PD et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids -a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211

    Article  Google Scholar 

  20. Cohen S, Levy RM, Keller M et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss -a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel group study. Arthritis Rheum 42:2309–2318

    Article  PubMed  CAS  Google Scholar 

  21. Lane NE, Sanchez S, Modin G et al (2000) Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled trial. J Bone Miner Res 15:944–951

    Article  PubMed  CAS  Google Scholar 

  22. Curtis JR, Westfall AO, Allison JJ et al (2005) Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 52:2486–2494

    Article  Google Scholar 

  23. Harrington JT, Barash HL, Day S, Lease J (2005) Redesigning the care of fragility fracture patients to improve osteoporosis management: a health care improvement project. Arthritis Rheum 53:198–204

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the specialists and primary care providers of the Geisinger Health System for their commitment and assistance in making this program a success and improving the lives of the patients whom we all serve.

Funding: This project was supported in part by an unrestricted educational grant from Merck & Co, Inc.

Author information

Authors and Affiliations

  1. Department of Rheumatology, Geisinger Medical Center, 100 N. Academy Avenue, Danville, PA, 17822-1341, USA

    E. D. Newman, C. K. Matzko, T. P. Olenginski, J. L. Perruquet, T. M. Harrington, G. Maloney-Saxon & T. Culp

  2. Center for Health Research and Rural Advocacy, Geisinger Health System, 100 N. Academy Avenue, Danville, PA, 17822-3003, USA

    G. C. Wood

Authors
  1. E. D. Newman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. K. Matzko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. P. Olenginski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. L. Perruquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. M. Harrington
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Maloney-Saxon
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. Culp
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. C. Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. D. Newman.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s00198-006-0198-7

Rights and permissions

Reprints and permissions

About this article

Cite this article

Newman, E.D., Matzko, C.K., Olenginski, T.P. et al. Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year. Osteoporos Int 17, 1428–1434 (2006). https://doi.org/10.1007/s00198-006-0149-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-006-0149-3

Keywords

Search

Navigation